Compare CNF & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNF | GBIO |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.5M | 36.3M |
| IPO Year | 2018 | 2020 |
| Metric | CNF | GBIO |
|---|---|---|
| Price | $5.66 | $5.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.88 |
| AVG Volume (30 Days) | 9.4K | ★ 89.9K |
| Earning Date | 02-27-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,241,013.00 | $15,270,000.00 |
| Revenue This Year | $252.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.36 | $3.00 |
| 52 Week High | $13.90 | $9.96 |
| Indicator | CNF | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 54.70 |
| Support Level | $4.00 | $5.41 |
| Resistance Level | $4.80 | $5.72 |
| Average True Range (ATR) | 0.49 | 0.13 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 82.96 | 79.27 |
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.